ZOMETA® Patient Case Study – Multiple Myeloma Medical Profile – Marie Is Not Alone

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Multiple Myeloma

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Multiple Myeloma Patient Case Study – Marie

Marie T.

Aged 62 years
Lives and works on a family farm
Enjoys walking her dogs with her husband

Page

1 2 3

Marie is not alone

70% to 95% of patients with advanced multiple myeloma will develop bone lesions¹
51% of patients with multiple myeloma and osteolytic disease will experience a skeletal-related event (SRE) without treatment²
SREs are generally defined as pathologic fractures, spinal compression, radiation or surgery to bone or tumor-induced hypercalcemia³

Page

1 2 3

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.